Multiple myeloma is the second most common hematologic cancer and remains incurable.
Several prognostic factors have been identified, but many are costly and inaccessible to most hematology centers.
To explore the clinical, laboratory, and cytogenetic factors that influence survival in patients with newly diagnosed multiple myeloma.
